Posted by Garnet71 on March 28, 2009, at 22:31:40
In reply to new paper on endocannabinoids and depression, posted by Larry Hoover on March 28, 2009, at 20:07:55
Hi Lar,
The first 150 words are avail on the site..but can't get the article from home...
A recent release from the European Medicines Agency has recommended the suspension of the weight-reducing drug rimonabant (which was also in trials for the treatment of nicotine dependence) from the market due to the development of undesirable psychiatric side effects, particularly symptoms of depression.1 This decision follows a similar one regarding rimonabant made by the US Food and Drug Administration last year for the same reasons. In November 2008, Sanofi-Aventis announced it was suspending marketing of rimonabant.2 Soon thereafter, Pfizer announced that it was terminating clinical trials with otenabant, a diet drug with a similar mechanism of action.3
Pharmacologically, rimonabant and otenabant act through antagonism of the cannabinoid CB1 receptor; thus, these clinical developments suggest that blockade of the CB1 receptor exerts adverse effects on emotional behavior and mood regulation. Given the therapeutic potential of these drugs for the treatment of obesity . . .
poster:Garnet71
thread:887459
URL: http://www.dr-bob.org/babble/20090322/msgs/887501.html